Actively Recruiting
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Led by Sun Yat-sen University · Updated on 2025-01-09
80
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
CONDITIONS
Official Title
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with recurrent hepatocellular carcinoma after curative treatment
- Tumor meets criteria for surgical removal
- At least one measurable tumor lesion per RECIST 1.1, untreated locally
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Child-Pugh liver function score between 5 and 7
- Agree to tumor biopsy and blood sample collection
- Adequate organ and bone marrow function
You will not qualify if you...
- Prior treatments including transarterial chemoembolization, immune therapy, or other local/systemic liver cancer therapies except curative ablation
- Presence of cancer spread outside the liver
- History of gastroesophageal varices or active stomach ulcers with bleeding risk
- History of autoimmune disease or long-term use of immunosuppressant drugs
- Positive test or history of HIV/AIDS
- Abnormal organ function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here